Shares of Santa Paula-based Calavo Growers faced another steep drop during the trading day Dec. 21, one day after the company’s fourth quarter and full-year earnings announcement. The company limped through the finish line in the fourth quarter, with both revenue and net income falling well below analysts’ expectations. It’s why Calavo’s stock fell as Read More →
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Elon Musk has been making headlines, mostly at his expense, nearly every day since his $44 billion purchase of Twitter. But for Dan O’Dowd, Musk’s Tesla software is no laughing matter. It has been nearly a year since Dan O’Dowd took out his first full-page newspaper advertisement, highlighting his disdain for Tesla’s assisted-driving technology. But the Read More →
Valeo Networks, a spinoff of Camarillo-based Saalex Solutions, announced Eric Ringelberg has been named the new president of the company, replacing Travis Mack, who will now move into a chairman role along with his CEO title. Valeo is headquartered in Rockledge, Florida but has operations in Camarillo. It is a managed security service provider, which Read More →
Thousand Oaks-based Atara Biotherapeutics announced on Dec. 19 that the European Commission has approved its drug, Ebvallo. Ebvallo, also known as tabelecleucel, has been Atara’s main product development in its pipeline since 2015. It is the first time Atara has received approval for one of its treatments. The drug is a monotherapy for the treatment Read More →